Treatment of adults with attention-deficit/hyperactivity disorder

Neuropsychiatric Disease and Treatment

Volumn 4, Issue 1 A, 2008, Pages 107-121

  Kolar, Dusan ^a   Keller, Amanda ^a   Golfinopoulos, Maria ^a   Cumyn, Lucy ^a   Syer, Cassidy ^a   Hechtman, Lily ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

Adult ADHD; Cognitive behavioral therapy; Medication; Stimulants

Indexed keywords

AMFEBUTAMONE; AMPHETAMINE; ANTIDEPRESSANT AGENT; ATOMOXETINE; BIPHENTIN; BUPROPION XL; CLONIDINE; DESIPRAMINE; DEXAMPHETAMINE; DEXEDRINE SPANULE; GUANFACINE; METHYLPHENIDATE; MODAFINIL; NEUROLEPTIC AGENT; PAROXETINE; PLACEBO; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; AGGRESSION; ANOREXIA; ANTISOCIAL BEHAVIOR; ANXIETY DISORDER; APPETITE; ATTENTION DEFICIT DISORDER; BIPOLAR DISORDER; BLURRED VISION; CARDIOTOXICITY; CLINICAL TRIAL; COGNITIVE THERAPY; COMBINATION CHEMOTHERAPY; COMORBIDITY; CONSTIPATION; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIASTOLIC BLOOD PRESSURE; DIFFERENTIAL DIAGNOSIS; DIZZINESS; DROWSINESS; DRUG DELIVERY SYSTEM; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG MECHANISM; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSURIA; ERECTILE DYSFUNCTION; GROWTH RETARDATION; HEADACHE; HEART RATE; HUMAN; HYPERTENSION; INSOMNIA; IRRITABILITY; LIBIDO; LIVER TOXICITY; MANIA; MENTAL DISEASE; MENTAL INSTABILITY; MONOTHERAPY; MOOD DISORDER; MORNING DOSAGE; NARCOLEPSY; NAUSEA; NERVOUSNESS; OPTIMAL DRUG DOSE; ORTHOSTATIC HYPOTENSION; PATIENT COMPLIANCE; PSYCHOSIS; PSYCHOTHERAPY; QT PROLONGATION; RATING SCALE; RECOMMENDED DRUG DOSE; REVIEW; SEDATION; SEIZURE; SEXUAL DYSFUNCTION; SIDE EFFECT; SUBSTANCE ABUSE; SUICIDE ATTEMPT; SWEATING; TACHYCARDIA; VISUAL HALLUCINATION; WEIGHT REDUCTION; XEROSTOMIA;

EID: 41549086255     PISSN: 11766328     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (81)

1. American Psychiatric Association. 2000. Diagnostic and statistical manual of mental disorder 4th edition text revision (DSM-IV-TR). Washington, DC: American Psychiatric Association.
2. Arnsten AF. 2006. Stimulants: Therapeutic actions in ADHD. Neuropsychopharmacology, 31:2376-83.
3. Arnsten AF, Dudley AG. 2005. Methylphenidate improves prefrontal cortical cognitive function through alpha2 adrenoceptor and dopamine D1 receptor actions: Relevance to therapeutic effects in attention deficit hyperactivity disorder. Behav Brain Funct, 1: 1-9.
4. Ballon JS, Feifel D. 2006. A systematic review of modafinil: potential clinical uses and mechanisms of action. J Clin Psychiatry, 67:554-66.
5. Barkley RA. 1990. Attention-deficit hyperactivity disorder: a handbook for diagnosis and treatment. New York: Guilford Publications.
6. Barkley RA, Fischer M, Smallish L, et al. 2004. Young adult follow-up of hyperactive children: antisocial activities and drug use. J Child Psychol Psychiatry, 45:195-211.
7. Barkley RA, Gordon M. 2002. Research on comorbidity, adaptive functioning, and cognitive impairments in adults with ADHD: Implications for a clinical practice. In: Goldstein S, Ellison AT eds. Clinician's Guide to Adult ADHD: Assessment and Intervention. San Diego: Academic Press. p43-67.
8. Barkley RA, Murphy KR, O'Connelld T, et al. 2005. Effects of two doses of methylphenidate on simulator driving performance in adults with attention deficit hyperactivity disorder. Journal of Safety Research, 36:121-31.
9. Belle DJ, Ernest SC, Sauer JM, et al. 2002. Effect of potent CYP2D6 inhibition by paroxetine on atomoxetine pharmacokinetics. J Clin Pharmacol, 42:1219-27.
10. Biederman J. 2004. Impact of comorbidity in adults with attention-deficit/hyperactivity disorder. J Clin Psychiatry, 65(Suppl 3):3-7.
11. Biederman J. 2006. Introduction: new developments in the treatment of attention-deficit/hyperactivity disorder. J Clin Psychiatry, 67(Suppl 8):3-6.
12. Biederman J, Mick E, Surman C, et al. 2006. A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry, 59:829-35.
13. Biederman J, Spencer T. 2002. Methylphenidate in treatment of adults with attention-deficit/hyperactivity disorder. J Atten Disord, 6(Suppl 1): 101-7.
14. Biederman J, Spencer TJ, Wilens TE, et al. 2005. Long-term safety and effectiveness of mixed amphetamine salts extended release in adults with ADHD. CNS Spectr, 10(Suppl 20):16-25.
15. CADORA. 2006. Canadian ADHD Practice Guidelines [online]. Umesh J, Hechtman L, Mutch C, et al. eds. Chapter 10 Appendices Medications for AD/HD, Toronto.
16. Coghill D, Seth S. 2006. Osmotic, controlled-release methylphenidate for the treatment of ADHD. Expert Opin Pharmacother, 7:2119-38.
17. Connor DF. 2005. Psychostimulants in attention deficit hyperactivity disorder. In: Gozal D, Molfese DL eds. Attention deficit hyperactivity disorder: from genes to patients. New Jersey: Humana Press. p 487-527.
18. Eakin L, Minde K, Hechtman L, et al. 2004. The marital and family functioning of adults with ADHD and their spouses. J Atten Disord, 8:1-10.
19. Fallu A, Caroline R, Prinzo R, et al. 2006. Does OROS-methylphenidate improve core symptoms and deficits in executive function? Results of an open-label trial in adults with attention deficit hyperactivity disorder. Curr Med Res Opin, 22:2557-66.
20. Faraone SV, Sergeant J, Gillberg C, et al. 2003. The worldwide prevalence of ADHD: Is it an American condition? World Psychiatry, 2:104-13.
21. Faraone SV, Spencer T, Aleardi M, et al. 2004. Meta-analysis of the efficacy of methylphenidate for treating adult attention-deficit/ hyperactivity disorder. J Clin Psychopharmacol, 24:24-9.
22. Fava M, Rush J, Thase ME, et al. 2005. 15 years of clinical experience with Bupropion HCL: From bupropion to Bupropion SR to Bupropion XL. Prim Care Companion. J Clin Psychiatry, 7:106-13.
23. Fawcett J. 2005, Sympathomimetics and dopamine receptor agonist. In: Sadock BJ, Sadock VA eds. Comprehensive Textbook of Psychiatry. Vol. 2. Philadelphia: Lippincott Williams and Wilkins. p 2938-43.
24. Fone KCF, Nutt DJ. 2005. Stimulants: use and abuse in the treatment of attention deficit hyperactivity disorder. Current Opinion in Pharmacology, 5:87-93.
25. Galina H, Looper K, Cousins L. Group cognitive-behavioural therapy manual for adult ADHD. Unpublished.
26. Greenhill LL. 2001. Clinical effects of stimulant medication in ADHD. In: Soltnao MV, Arnsten AFT, Castellanos FX eds. Stimulant Drugs and ADHD: Basic and Clinical Neuroscience. New York: Oxford University Press. p 31-57.
27. Greenhill LL, Abikoff HB, Arnold LE, et al. 1996. Medication treatment strategies in the MTA Study: relevance to clinicians and researchers. J Am Acad Child Adolesc Psychiatry, 35:1304-13.
28. Hechtman L. 2005. Attention deficit disorders. In: Sadock BJ, Sadock VA eds.Comprehensive Textbook of Psychiatry. Vol. 2. Philadelphia: Lippincott Williams and Wilkins. p 3183-98.
29. Hechtman L, Brown T, Greenfield B, et al. 2003. Treatment of adults with attention deficit hyperactivity disorder and varying degrees of anxiety and depression: Treatment safety and efficacy. Oral presentation. Miami: 50th Annual of the American Academy of Child and Adolescent Psychiatry
30. Hechtman L, Etcovitch J, Platt R, et al. 2005. Does multimodal treatment of ADHD decrease other diagnoses? Clin Neurosci Res, 5:273-82.
31. Hesslinger B, Tebartz van Elst L, Nyberg E, et al. 2002. Psychotherapy of attention deficit hyperactivity disorder in adults - a pilot study using a structured skills training program. Eur Arch Psychiatry Clin Neurosci, 252:177-84.
32. Jain U, Hechtman L, Weiss M, et al. 2007. Efficacy of a novel biphasic controlled-release methylphenidate formula in adults with attention-deficit/hyperactivity disorder: Results of a double-blind, placebo-controlled crossover study. J Clin Psychiatry, 68:268-77.
33. James RS, Sharp WS, Bastain TM, et al. 2001. Double-blind, placebo-controlled study of single-dose amphetamine formulations in ADHD. J Am Acad Child Adolesc Psychiatry, 40:1268-76.
34. Kessler RC, Adler L, Ames M, et al. 2005. The prevalence and effects of adult attention deficit/hyperactivity disorder on work performance in a nationally representative sample of workers. J Occup Environ Med, 47:565-72.
35. Kessler RC, Adler LA, Barkley R, et al. 2006. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry, 163:716-23.
36. Kollins SH, MacDonald EK, Rush CR. 2001. Assessing the abuse potential of methylphenidate in nonhuman and human subjects: a review. Pharmacol Biochem Behav, 68:611-27.
37. Krause KH, Dresel SH, Krause J, et al. 2000. Increased striatal dopamine transporter in adult patients with attention deficit hyperactivity disorder: effects of methylphenidate as measured by single photon emission tomography. Neurosci Lett, 285:107-10.
38. Lindsay SE, Gudelsky GA, Heaton PC. 2006. Use of modafinil for the treatment of attention deficit/hyperactivity disorder. Ann Pharmacother, 40:1829-33.
39. Lopez F. 2006. ADHD: New pharmacological treatments on the horizon. J Dev Behav Pediatr, 27:410-16.
40. Mannuzza S, Klein RG, Bessler A, et al. 1998. Adult psychiatric status of hyperactive boys grown up. Am J Psychiatry, 155:493-8.
41. McGough JJ, Yang M, McCracken JT, et al. 2005. Psychiatric comorbidity in adult attention deficit hyperactivity disorder: findings from multiplex families. Am J Psychiatry, 162:1621-7.
42. McLean A, Dowson B, Toone S, et al. 2004. Characteristic neurocognitive profile associated with adult attention-deficit/hyperactivity disorder. Psycholog Med, 34:681-92.
43. Michelson D, Adler L, Spencer T, et al. 2003. Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol Psychiatry, 53:112-20.
44. MTA Cooperative Group. 1999. A 14-month randomized clinical trial of treatment strategies for attention deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD. Arch Gen Psychiatry, 56:1073-86.
45. Murphy K. 2005. Psychosocial treatments for ADHD in teens and adults: a practice-friendly review. J Clin Psychol, 61:607-19.
46. Nutt DJ, Fone K, Asherson P, et al. 2006. Evidence-based guidelines for management of attention-deficit/hyperactivity disorder in adolescents in transition to adult services and in adults: recommendations from the British Association for Psychopharmacology. J Psychopharmacol, 8:1-32.
47. Pliszka SR. 2007. Phramacologic treatment of attention-deficit/ hyperactivity disorder: efficacy, safety, and mechanism of action. Neuropsychol Rev, 23.
48. Powers AC. 2000. The pharmacology of drugs used for the treatment of attention deficit hyperactivity disorder. In: Accardo PJ, Blondis TA, Whitman BY, et al. eds. Attention deficits and hyperactivity in children and adults: diagnosis, treatment, management. New York: Marcel Dekker, Inc. p 477-511.
49. Prince BJ, Wilens TE. 2000. Diagnosis and treatment of adults with ADHD. In: Accardo PJ, Blondis TA, Whitman BY, et al. eds. Attention deficits and hyperactivity in children and adults: diagnosis, treatment, management. New York: Marcel Dekker, Inc. p 665-82.
50. Rapport MD, Chung KM, Shore G et al. 2001. A conceptual model of child psychopathology: Implications for understanding attention deficit hyperactivity disorder and treatment efficacy. J Child Clin Psychol, 30:48-58.
51. Paykina N, Greenhill LL, Gorman JM. 2007. Pharmacological treatments for attention-deficit/hyperactivity disorder. In: Nathan PE, Gorman JM eds. A guide to treatments that work. Third Edition. New York: Oxford University Press. p 29-39.
52. Reimherr FW, Williams ED, Strong RE, et al. 2007. A double-blind, placebo-controlled, crossover study of osmotic release oral system methylphenidate in adults with ADHD with assessment of oppositional and emotional dimensions of the disorder. J Clin Psychiatry, 68:93-101.
53. Robertson MM. 2006. Attention deficit hyperactivity disorder, tics and Tourette's syndrome: the relationship and treatment implications. A commentary. Eur Child Adolesc Psychiatry, 15: 1-11.
54. Rosler M, Retz W, Thome J, et al. 2006. Psychopathological rating scales for diagnostic use in adults with attention-deficit/hyperactivity disorder (ADHD). Eur Arch Psychiatry Clin Neurosci, 256 Suppl 1:i3-11.
55. Rostain AL, Ramsay RJ. 2006. A combined treatment approach for adults with ADHD - Results of an open study of 43 patients. J of Att Dis, 10:150-9.
56. Sobanski E. 2006. Psychiatric comorbidity in adults with attention-deficit/hyperactivity disorder (ADHD). Eur Arch Psychiatry Clin Neurosci, 256:126-31.
57. Safren SA. 2006. Cognitive-behavioral approaches to ADHD treatment in adulthood. J Clin Psychiatry, 67(Suppl 8):46-50.
58. Safren SA, Otto MW, Sprich S, et al. 2004. Cognitive-behavioral therapy for ADHD in medication-treated adults with continued symptoms. Behav Res Ther, 43:792-801.
59. Spencer TJ, Biederman J, Mick E. 2007. Attention-deficit/hyperactivity disorder: diagnosis, lifespan, comorbidities, and neurobiology. Ambul Pediatr, 7(1 Suppl):73-81.
60. Spencer T, Biederman J, Wilens T, et al. 1998. Effectiveness and tolerability of tomoxetine in adults with attention deficit hyperactivity disorder. Am J Psychiatry, 155:693-5.
61. Spencer T, Biederman J, Wilens T. 2004. Nonstimulant treatment of adult attention-deficit/hyperactivity disorder. Psychiatr Clin N Am, 27:373-83.
62. Spencer T, Biederman J, Wilens T, et al. 2005. A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. Biol Psychiatry, 57:456-63.
63. Spencer TJ, Faraone SV, Michelson D, et al. 2006. Atomoxetine and adult attention-deficit/hyperactivity disorder: the effects of comorbidity. J Clin Psychiatry, 67:415-20.
64. Stevenson CS, Whitmont S, Bornholt L, et al. 2002. A cognitive remediation programme for adults with attention deficit hyperactivity disorder. Austral NZ J Psychiatry, 36:610-16.
65. Taylor FB, Russo J. 2001. Comparing guanfacine and dextroamphetamine for the treatment of adult attention-deficit/hyperactivity disorder. J Clin Psychopharmacol, 21:223-8.
66. Turner D. 2006. A review of the use of modafinil for attention-deficit hyperactivity disorder. Expert Rev Neurother, 6:455-68.
67. Weiss G, Hechtman L. 1993. Hyperactive children grownup: ADHD in children, adolescents, and adults. New York: Guilford Pressp 366-81.
68. Weiss M, Hechtman L, Adult ADHD Research Group. 2006. A randomized double-blind trial of paroxetine and/or dextroamphetamine and problem-focused therapy for attention-deficit/hyperactivity disorder in adults. J Clin Psychiatry, 67:611-19.
69. Weiss M, Hechtman Trokenberg L, Weiss G. 1999. ADHD in adulthood: a guide to current theory, diagnosis, and treatment. Baltimore: John Hopkins University Press. p 132-67.
70. Weiss M, Murray C, Weiss G. 2002. Adults with attention-deficit/ hyperactivity disorder: current concepts. J Psychiatr Pract, 82:99-111.
71. Weiss M, Shingler T, Capone NM. 2006. Medication satisfaction among adults with ADHD: long term results from the Quality of Life, Effectiveness, Safety, and Tolerability (Qu S.T.) study. New Orleans: Program and abstracts of the 19th US Psychiatric and Mental Health Congress; Abstract 120.
72. Weiss M, Weiss JR. 2004. A guide to the treatment of adults with ADHD. J Clin Psych, 65(Suppl 3):27-37.
73. Wilens T, 2004a. Attention-deficit/hyperactivity disorder and the substance use disorders: the nature of the relationship, subtypes at risk, and treatment issues. Psychiatr Clin North Am, 27:283-301.
74. Wilens TE. 2004b. Impact of ADHD and Its Treatment on Substance Abuse in Adults. J Clin Psychiatry, 65(Suppl 3):38-45.
75. Wilens TE. 2006. Mechanism of action of agents used in attention-deficit/ hyperactivity disorder. J Clin Psychiatry, 67(Suppl 8):32-7.
76. Wilens TE, Haight BR, Horrigan JP, et al. 2005. Bupropion XL in adults with attention-deficit/hyperactivity disorder: A randomized, placebo-controlled study. Biol Psychiatry, 57:793-801.
77. Wilens TE, McDermott SP, Biederman J, et al. 1999. Cognitive therapy in the treatment of adults with ADHD: a systematic chart review of 26 cases. J Cognitive Psychother, 13:215-22.
78. Wilens TE, Prince JB, Spencer T, et al. 2003. An open trial of bupropion for the treatment of adults with attention-deficit/hyperactivity disorder and bipolar disorder. Biol Psychiatry, 54:9-16.
79. Wilens TE, Spencer TJ, Biederman J. 2002. Attention deficit/ hyperactivity disorder across the life span. Ann Rev Med, 53:113-31.
80. Wilens TE, Zusman RA, Hammerness PG, et al. 2006. An open-label study of the tolerability of mixed amphetamine salts in adults with attention-deficit/hyperactivity disorder and treated primary essential hypertension. J Clin Psychiatry, 67:696-702.
81. Young S. 2002. A model of psychotherapy for adults with ADHD. In: Goldstein S, Ellison AT eds. Clinician's guide to adult ADHD: assessment and intervention. San Diego: Academic Press. p 147-58.